Resumen ejecutivo de ARIA 2019: Vías integradas de atención para la rinitis alérgica en Argentina, España y México.

Juan Carlos Ivancevich, Victoria Cardona, Désirée Larenas-Linnemann, Joaquim Mullol, Hugo Neffen, Mario Zernotti, Estrella Asayag, Ariel Eduardo Blua, R. Maximiliano Gómez, Edgardo Jares, Jorge Máspero, Josep M. Anto, Toni Dedeu, Mónica Rodríguez-González, Yunuen Rocío Huerta-Villalobos, José Miguel Fuentes-Pérez, Eréndira Rodríguez-Zagal, Antonio Valero, Joan Bartra, Isam Alobid, José Antonio Castillo-Vizuete, Teresa Dordal, Rafael Hijano, César Picado, Joaquín Sastre, Martín Bedolla-Barajas, María Teresa Burguete-Cabañas, María del Carmen Costa-Domínguez, Margarita Domínguez-Silva, Jesús Guillermo Espinoza-Contreras, José Luis Gálvez-Romero, Cecilia Yvonne García-Cobas, María de la Luz Hortensia García-Cruz, Luiana Hernández-Velázquez, Jorge A. Luna-Pech, Juan José Matta, María Dolores Mogica-Martínez, Daniela Rivero-Yeverino, Lucy Tania Ruiz, Blanca E. Del Río-Navarro, Javier Gómez-Vera, Alejandra Macías-Weinmann, Ionna Agache, Ignacio Ansotegui, Claus Bachert, Anna Bedbrook, Giorgio Walter Canonica, Thomas B. Casale, Álvaro Cruz, Wytske Fokkens, Peter Hellings, Bolesław Samolinski, Jean Bousquet

Resumen


El impacto sanitario y económico de las enfermedades alérgicas está aumentando rápidamente y se necesitan cambios en las estrategias para su manejo. Su influencia reduce al menos en un tercio la capacidad de desempeño laboral y escolar. Los ICP (Vías Integradas de Atención) de las enfermedades de las vías respiratorias son planes de atención estructurados y multidisciplinarios, que promueven las recomendaciones de las guías en protocolos locales y su aplicación a la práctica clínica. En este documento se presenta un resumen ejecutivo para Argentina, México y España. Se desarrollan las guías ARIA de próxima generación para el tratamiento farmacológico de la rinitis alérgica (RA) utilizando las pautas basadas en GRADE para RA, probadas con evidencia de la vida real proporcionada por tecnología móvil basada en escalas visuales analógicas. Se concluye que en el tratamiento de la RA, los antihistamínicos anti-H1 son menos efectivos que los corticoides intranasales (CINS), que en la rinitis grave los CINS representan la primera línea de tratamiento, y que la combinación intranasal de CINS + anti-H1 es más eficaz que la monoterapia. Sin embargo, según el estudio MASK observacional en vida real, los pacientes tienen pobre adherencia al tratamiento y frecuentemente se automedican de acuerdo con sus necesidades.


Palabras clave


ARIA; Rinitis alérgica; Vías integradas de atención; Estudios en vida real; Adherencia; Automedicación

Texto completo:

PDF PubMed (English)

Referencias


Bousquet J, Hellings PW, Agache I, Amat F, Annesi-Maesano I, Ansotegui IJ, 4. ARIA Phase 4 (2018): change management in allergic rhinitis and asthma multimorbidity using mobile technology. J Allergy Clin Immunol. 2019;143(3):864-879. DOI: 10.1016/j.jaci.2018.08.049

Asher MI, Keil U, Anderson HR, Beasley R, Crane J, Martinez F, et al. International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. Eur Respir J. 1995;8(3):483-491. DOI: 10.1183/09031936.95.08030483

Aït-Khaled N, Pearce N, Anderson HR, Ellwood P, Montefort S, Shah J, et al. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three. Allergy. 2009;64(1):123-148. DOI: 10.1111/j.1398-9995.2008.01884.x

Chong-Neto HJ, Rosário NA, Solé D, Latin American ISAAC Group. Asthma and rhinitis in South America: how different they are from other parts of the world. Allergy Asthma Immunol Res. 2012;4(2):62-67. DOI: 10.4168/aair.2012.4.2.62

Vázquez D, Medina I, Logusso G, Gattolin G, Arias S, Parisi C. Cross-sectional prevalence survey of allergic rhinitis in Argentina: Study PARA. Rev Alerg Mex. 2019;66(1):55-64. DOI: 10.29262/ram.v66i1.543

Neffen H, Mello JF, Solé D, Naspitz CK, Dodero AE, Garza HL, et al. Nasal allergies in the Latin American population: results from the Allergies in Latin America survey. Allergy Asthma Proc. 2010;31(Suppl 1):S9-S27. DOI: 10.2500/aap.2010.31.3347

Maspero JF, Jardim JR, Aranda A, Tassinari CP, González-Díaz SN, Sansores RH, et al. Insights, attitudes, and perceptions about asthma and its treatment: findings from a multinational survey of patients from Latin America. World Allergy Organ J. 2013;6(1):19. DOI: 10.1186/1939-4551-6-19

Strachan D, Sibbald B, Weiland S, Aït-Khaled N, Anabwani G, Anderson HR, et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Allergy Immunol. 1997;8(4):161-176. DOI: 10.1111/j.1399-3038.1997.tb00156.x

Björkstén B, Clayton T, Ellwood P, Stewart A, Strachan D, ISAAC Phase III Study Group. Worldwide time trends for symptoms of rhinitis and conjunctivitis: Phase III of the International Study of Asthma and Allergies in Childhood. Pediatr Allergy Immunol. 2008;19(2):110-124. DOI: 10.1111/j.1399-3038.2007.00601.x

Arnedo-Pena A, García-Marcos L, García-Hernández G, Aguinagua-Ontoso I, González-Díaz C, Morales-Suárez-Varela M, et al. Time trends and geographical variations in the prevalence of symptoms of allergic rhinitis in 6-7-year-old children from eight areas of Spain according to the ISAAC. An Pediatr (Barc). 2005;62(3):229-236. DOI: 10.1157/13071837

Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004;24(5):758-764. DOI: 10.1183/09031936.04.00013904

Vicente-Herrero MT, Prieto-Andrés L, López-González AA, Pérez-Francés C, Ramírez-Íñiguez de la Torre MV, Santamaría-Navarro C, et al. Prevalence of rhinitis and asthma respiratory symptoms in Spanish working population. Rev Med Inst Mex Seguro Soc. 2014;52(1):50-59.

Ojeda P, Sastre J, Olaguibel JM, Chivato T. Alergológica 2015: a national survey on allergic diseases in the adult Spanish population. J Investig Allergol Clin Immunol. 2018;28(3):151-164. DOI: 10.18176/jiaci.0264

Ojeda P, Ibáñez MD, Olaguibel JM, Sastre J, Chivato T. Alergológica 2015: a national survey on allergic diseases in the Spanish pediatric population. J Investig Allergol Clin Immunol. 2018;28(5):321-329. DOI: 10.18176/jiaci.0308

Valero A, Ferrer M, Sastre J, Navarro AM, Monclús L, Martí-Guadaño E, et al. A new criterion by which to discriminate between patients with moderate allergic rhinitis and patients with severe allergic rhinitis based on the Allergic Rhinitis and its Impact on Asthma severity items. J Allergy Clin Immunol. 2007;120(2):359-365. DOI: 10.1016/j.jaci.2007.04.006

ESPRINT Study Group and Investigators, Valero A, Alonso J, Antepara I, et al. Development and validation of a new Spanish instrument to measure health-related quality of life in patients with allergic rhinitis: the ESPRINT questionnaire. Value Health. 2007;10(6):466- 77. DOI: 10.1111/j.1524-4733.2007.00202.x

Janson C, Antó J, Burney P, Chinn S, de Marco R, Heinrich J, et al. The European Community Respiratory Health Survey: what are the main results so far? European Community Respiratory Health Survey II. Eur Respir J. 2001;18(3):598-611. DOI: 10.1183/09031936.01.00205801

Mancilla-Hernández E, Barnica-Alvarado RH, Morfín-Maciel B, Larenas-Linnemann D. Validation of a diagnostic questionnaire on asthma in children and adults for epidemiological studies. Rev Alerg Mex. 2014;61(2):73-80. DOI: 10.29262/ram.v61i2.29

Mancilla-Hernandez E, Medina-Ávalos MA, Barnica-Alvarado RH, Soto-Candia D, Guerrero-Venegas R, Zecua-Nájera Y. Prevalence of rhinitis allergic in populations of several states of Mexico. Rev Alerg Mex. 2015;62(3):196-201. DOI: 10.29262/ram.v62i3.107

Mancilla-Hernández E, González-Solórzano E. Prevalence of allergic rhinitis, and symptoms as indicators of risk in schoolchildren of the Puebla Northern Mountain Range. Rev Alerg Mex. 2018;65(2):140-147. DOI: 10.29262/ram.v65i2.330

Ramírez-Soto M, Bedolla-Barajas M, González-Mendoza T. Prevalence of asthma, allergic rhinitis and atopic dermatitis in school children of the Mexican Bajío region. Rev Alerg Mex. 2018;65(4):372-378. DOI: 10.29262/ram.v65i4.527

Bousquet J, Anto JM, Annesi-Maesano I, Dedeu T, Dupas E, Pepin JL, et al. POLLAR: impact of air POLLution on asthma and rhinitis; a European Institute of Innovation and Technology Health (EIT Health) project. Clin Transl Allergy. 2018;8:36. Disponible en: https://ctajournal.biomedcentral.com/articles/10.1186/s13601-018-0221-z

Bousquet J, Arnavielhe S, Bedbrook A, Bewick M, Laune D, Mathieu-Dupas E, et al. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. Clin Transl Allergy. 2018;8:45. DOI: 10.1186/s13601-018-0227-6

Campbell H, Hotchkiss R, Bradshaw N, Porteous M. Integrated care pathways. BMJ. 1998;316(7125):133-137. DOI: 10.1136/bmj.316.7125.133

Hujala A, Taskinen H, Rissanen S. How to support integration to promote care for people with multimorbidity in Europe? Alemania: European Observatory Policy Briefs; 2017.

Palmer K, Marengoni A, Forjaz MJ, Jureviciene E, Laatikainen T, Mammarella F, et al. Multimorbidity care model: recommendations from the consensus meeting of the Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS). Health Policy. 2018;122(1):4-11. DOI: 10.1016/j.healthpol.2017.09.006

Bousquet J, Addis A, Adcock I, Agache I, Agusti A, Alonso A, et al. Integrated care pathways for airway diseases (AIRWAYS-ICPs). Eur Respir J. 2014;44(2):304-323. DOI: 10.1183/09031936.00014614

Meltzer EO, Wallace D, Dykewicz M, Shneyer L. Minimal Clinically Important Difference (MCID) in allergic rhinitis: agency for healthcare research and quality or anchor-based thresholds? J Allergy Clin Immunol Pract. 2016;4(4):682-688. DOI: 10.1016/j.jaip.2016.02.006

Muñoz-Cano R, Ribó P, Araujo G, Giralt E, Sánchez-López J, Valero A. Severity of allergic rhinitis impacts sleep and anxiety: results from a large Spanish cohort. Clin Transl Allergy. 2018;8:23. Disponible en: https://ctajournal.biomedcentral.com/articles/10.1186/s13601-018-0212-0

Vandenplas O, Vinnikov D, Blanc PD, Agache I, Bachert C, Bewick M, et al. Impact of rhinitis on work productivity: a systematic review. J Allergy Clin Immunol Pract. 2018;6(4):1274-1286. DOI: 10.1016/j.jaip.2017.09.002

Bousquet J, Schunemann HJ, Hellings PW, Arnavielhe S, Bachert C, Bedbrook A, et al. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol. 2016;138(2):367-374. DOI: 10.1016/j.jaci.2016.03.025

Courbis AL, Murray RB, Arnavielhe S, Caimmi D, Bedbrook A, van Eerd M, et al. Electronic clinical decision support system for allergic rhinitis management: MASK e-CDSS. Clin Exp Allergy. 2018;48(12):1640-1653. DOI: 10.1111/cea.13230

Use of real-world evidence to support regulatory decision-making for medical devices. EE.UU.: Guidance for Industry and Food and Drug Administration Staff; 2017.

Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence. What is it and what can it tell us? N Engl J Med. 2016;375(23):2293-2297. DOI: 10.1056/NEJMsb1609216

Briere JB, Bowrin K, Taieb V, Millier A, Toumi M, Coleman C. Meta-analyses using real-world data to generate clinical and epidemiological evidence: a systematic literature review of existing recommendations. Curr Med Res Opin. 2018;34(12):2125-2130. DOI: 10.1080/03007995.2018.1524751

Brozek JL, Akl EA, Alonso-Coello P, Lang D, Jaeschke R, Williams JW, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy. 2009;64(5):669-677. DOI: 10.1111/j.1398-9995.2009.01973.x

Brozek JL, Akl EA, Compalati E, Kreis J, Terracciano L, Fiocchi A, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy. 2011;66(5):588-595. DOI: 10.1111/j.1398-9995.2010.02530.x

Brozek JL, Akl EA, Jaeschke R, Lang DM, Bossuyt P, Glasziou P, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines: part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies. Allergy. 2009;64(8):1109-1116. DOI: 10.1111/j.1398-9995.2009.02083.x

Oyinlola JO, Campbell J, Kousoulis AA. Is real world evidence influencing practice? A systematic review of CPRD research in NICE guidances. BMC Health Serv Res. 2016;16:299. DOI: 10.1186/s12913-016-1562-8

Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466-476. DOI: 10.1016/j.jaci.2010.06.047

Brozek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950-958. DOI: 10.1016/j.jaci.2017.03.050

Dykewicz MS, Wallace DV, Baroody F, Bernstein J, Craig T, Finegold I, et al. Treatment of seasonal allergic rhinitis: an evidence-based focused 2017 guideline update. Ann Allergy Asthma Immunol. 2017;119(6):489-511. DOI: 10.1016/j.anai.2017.08.012

Bousquet J, Arnavielhe S, Bedbrook A, Alexis-Alexandre G, van Eerd M, Murray R, et al. Treatment of allergic rhinitis using mobile technology with real world data: The MASK observational pilot study. Allergy. 2018;73(9):1763-1774. DOI: 10.1111/all.13406

Klimek L, Bergmann KC, Biedermann T, Bousquet J, Hellings P, Jung K, et al. Visual analogue scales (VAS): measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: position paper of the German Society of Allergology (AeDA) and the German Society of Allergy and Clinical Immunology (DGAKI), ENT Section, in collaboration with the working group on Clinical Immunology, Allergology and Environmental Medicine of the German Society of Otorhinolaryngology, Head and Neck Surgery (DGHNOKHC). Allergo J Int. 2017;26(1):16-24. DOI: 10.1007/s40629-016-0006-7

Horak F, Bruttmann G, Pedrali P, Weeke B, Frolund L, Wolff HH, et al. A multicentric study of loratadine, terfenadine and placebo in patients with seasonal allergic rhinitis. Arzneimittelforschung. 1988;38(1):124-128.

Hampel FC, Ratner PH, van Bavel J, Amar NJ, Daftary P, Wheeler W, et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol. 2010;105(2):168-173. DOI: 10.1016/j.anai.2010.06.008

Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129(5):1282-1289. DOI: 10.1016/j.jaci.2012.01.077

Kaszuba SM, Baroody FM, de Tineo M, Haney L, Blair C, Naclerio RM. Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. Arch Intern Med. 2001;161(21):2581-2587. DOI: 10.1001/archinte.161.21.2581

Glacy J, Putnam K, Godfrey S, Falzon L, Mauger B, Samson D, et al. Treatments for seasonal allergic rhinitis. EE.UU.: Agency for Healthcare Research and Quality; 2013.

Scadding GK, Durham SR, Mirakian R, Jones NS, Leech SC, Farooque S, et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy. 2008;38(1):19-42. DOI: 10.1111/j.1365-2222.2007.02888.x

Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122(Suppl 2):S1-S84. DOI: 10.1016/j.jaci.2008.06.003

Roberts G, Xatzipsalti M, Borrego LM, Custovic A, Halken S, Hellings PW, et al. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2013;68(9):1102-1116. DOI: 10.1111/all.12235.

Scadding GK. Optimal management of allergic rhinitis. Arch Dis Child. 2015;100(6):576-582. DOI: 10.1136/archdischild-2014-306300

Larenas-Linnemann D, Mayorga-Butron JL, Sánchez-González A, Ramírez-García A, Medina-Ávalos M, Figueroa-Morales MA, et al. ARIA Mexico 2014. Adaptation of the clinical practice guide ARIA 2010 for Mexico. Methodology ADAPTE. Rev Alerg Mex. 2014;61(Suppl 1):S3-S116. Disponible en: http://revistaalergia.mx/ojs/index.php/ram/article/view/52/69

Meltzer EO. Pharmacotherapeutic strategies for allergic rhinitis: matching treatment to symptoms, disease progression, and associated conditions. Allergy Asthma Proc. 2013;34(4):301-311.

Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR, et al. Clinical practice guideline: allergic rhinitis executive summary. Otolaryngol Head Neck Surg. 2015;152(2):197-206. DOI: 10.2500/aap.2013.34.3676

Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR, et al. Clinical practice guideline: allergic rhinitis. Otolaryngol Head Neck Surg. 2015;152(Suppl 1):S1-S43. DOI: 10.1177/0194599814561600

Bousquet J, Meltzer EO, Couroux P, Koltun A, Kopietz F, Munzel U, et al. Onset of action of the fixed combination intranasal azelastine-fluticasone propionate in an allergen exposure chamber. J Allergy Clin Immunol Pract. 2018;6(5):1726-1732. DOI: 10.1016/j.jaip.2018.01.031

Bachert C, Bousquet J, Hellings P. Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management. Clin Transl Allergy. 2018;8:25. Disponible en: https://ctajournal.biomedcentral.com/articles/10.1186/s13601-018-0210-2

Church MK, Maurer M, Simons FE, Bindslev-Jensen C, van Cauwenberge P, Bousquet J, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy. 2010;65(4):459-466. DOI: 10.1111/j.1398-9995.2009.02325.x

Allergic rhinitis: developing drug products for treatment. Guidance for industry. EE.UU.: U.S. Department of Health and Human Services/Food and Drug Administration/Center for Drug Evaluation and Research; 2000.

Allergic rhinitis: developing drug products for treatment. Guidance for industry. EE.UU.: U.S. Department of Health and Human Services/Food and Drug Administration/Center for Drug Evaluation and Research; 2016.

Katial RK, Salapatek AM, Patel P. Establishing the onset of action of intranasal corticosteroids: is there an ideal study design? Allergy Asthma Proc. 2009;30(6):595-604. DOI: 10.2500/aap.2009.30.3291

Pfaar O, Calderon MA, Andrews CP, Angjeli E, Bergmann KC, Bonlokke JH, et al. Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future-an EAACI position paper. Allergy. 2017;72(7):1035-1042. DOI: 10.1111/all.13133

Patel P, D’Andrea C, Sacks HJ. Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber. Am J Rhinol. 2007;21(4):499-503. DOI: 10.2500/ajr.2007.21.3058

Patel P, Roland PS, Marple BF, Benninger PJ, Margalias H, Brubaker M, et al. An assessment of the onset and duration of action of olopatadine nasal spray. Otolaryngol Head Neck Surg. 2007;137(6):918-924. DOI: 10.1016/j.otohns.2007.08.005

Salapatek AM, Lee J, Patel D, D’Angelo P, Liu J, Zimmerer RO, et al. Solubilized nasal steroid (CDX-947) when combined in the same solution nasal spray with an antihistamine (CDX-313) provides improved, fast-acting symptom relief in patients with allergic rhinitis. Allergy Asthma Proc. 2011;32(3):221-229. DOI: 10.2500/aap.2011.32.3444

Horak F, Zieglmayer UP, Zieglmayer R, Kavina A, Marschall K, Munzel U, et al. Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy. Curr Med Res Opin. 2006;22(1):151-157. DOI: 10.1185/030079906X80305

Zieglmayer P, Zieglmayer R, Bareille P, Rousell V, Salmon E, Horak F. Fluticasone furoate versus placebo in symptoms of grass-pollen allergic rhinitis induced by exposure in the Vienna Challenge Chamber. Curr Med Res Opin. 2008;24(6):1833-1840. DOI: 10.1185/03007990802155792

Murdoch RD, Bareille P, Ignar D, Miller SR, Gupta A, Boardley R, et al. The improved efficacy of a fixed-dose combination of fluticasone furoate and levocabastine relative to the individual components in the treatment of allergic rhinitis. Clin Exp Allergy. 2015;45(8):1346-1355. DOI: 10.1111/cea.12556

Sleurs K, Seys S, Bousquet J, Fokkens W, Gorris S, Pugin B, et al. Mobile health tools for the management of chronic respiratory diseases. Allergy. 2019;74(7):1292-1306. DOI: 10.1111/all.13720

Bousquet J, Hellings PW, Agache I, Bedbrook A, Bachert C, Bergmann KC, et al. ARIA 2016: care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clin Transl Allergy. 2016;6:47. Disponible en : https://ctajournal.biomedcentral.com/articles/10.1186/s13601-016-0137-4

Bédard A, Basagaña X, Anto JM, Garcia-Aymerich J, Devillier P, Arnavielhe S, et al. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. J Allergy Clin Immunol. 2019;144(1):135-143. DOI: 10.1016/j.jaci.2019.01.053

Menditto E, Guerriero F, Orlando V, Crola C, Di Somma C, Illario M, et al. Self-assessment of adherence to medication: a case study in Campania region community-dwelling population. J Aging Res. 2015;2015:682503. DOI: 10.1155/2015/682503

Caimmi D, Baiz N, Tanno LK, Demoly P, Arnavielhe S, Murray R, et al. Validation of the MASK-rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control. Clin Exp Allergy. 2017;47(12):1526-1533. DOI: 10.1111/cea.13025

Bonini M. Electronic health (e-Health): emerging role in asthma. Curr Opin Pulm Med. 2017;23(1):21-26. DOI: 10.1097/MCP.0000000000000336

Pizzulli A, Perna S, Florack J, Pizzulli A, Giordani P, Tripodi S, et al. The impact of telemonitoring on adherence to nasal corticosteroid treatment in children with seasonal allergic rhinoconjunctivitis. Clin Exp Allergy. 2014;44(10):1246-1254. DOI: 10.1111/cea.12386

Bousquet J, Caimmi DP, Bedbrook A, Bewick M, Hellings PW, Devillier P, et al. Pilot study of mobile phone technology in allergic rhinitis in European countries: the MASK-rhinitis study. Allergy. 2017;72(6):857-865. DOI: 10.1111/all.13125

Bousquet J, Arnavielhe S, Bedbrook A, Fonseca J, Morais-Almeida M, Todo-Bom A, et al. The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study. Allergy. 2018;73(2):505-510. DOI: 10.1111/all.13307

Bousquet J, Devillier P, Anto JM, Bewick M, Haahtela T, Arnavielhe S, et al. Daily allergic multimorbidity in rhinitis using mobile technology: a novel concept of the MASK study. Allergy. 2018;73(9):1763-1774. DOI: 10.1111/all.13448

Bousquet J, VandenPlas O, Bewick M, Arnavielhe S, Bedbrook A, Murray R, et al. The Work Productivity and Activity Impairment Allergic Specific (WPAI-AS) questionnaire using mobile technology: The MASK Study. J Investig Allergol Clin Immunol. 2018;28(1):42-44. DOI: 10.18176/jiaci.0197

Price D, Scadding G, Ryan D, Bachert C, Canonica GW, Mullol J, et al. The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey. Clin Transl Allergy. 2015;5:39. Disponible en: https://ctajournal.biomedcentral.com/articles/10.1186/s13601-015-0083-6

Bousquet J, Murray R, Price D, Somekh D, Münter L, Phillips J, et al. The allergic allergist behaves like a patient. Ann Allergy Asthma Immunol. 2018;121(6):741-742. DOI: 10.1016/j.anai.2018.07.034

Couroux P, Kunjibettu S, Kunjibettu S, Hall N, Wingertzahn MA. Onset of action of ciclesonide once daily in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2009;102(1):62-68. DOI: 10.1016/S1081-1206(10)60110-X

Bousquet J, Schünemann H, Togias A, Bachert C, Erhola M, Hellings P, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70-80. DOI: 10.1016/j.jaci.2019.06.049




DOI: http://dx.doi.org/10.29262/ram.v66i4.643

Enlaces refback

  • No hay ningún enlace refback.


Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.